HUTCHMED (China) Ltd ADR HCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
Trading Information
- Previous Close Price
- $14.20
- Day Range
- $14.44–15.31
- 52-Week Range
- $9.77–16.33
- Bid/Ask
- $14.35 / $15.50
- Shares Outstanding
- 173.81M
- Market Cap
- $2.64B
- Volume/Avg
- 157,312 / 69,667
Key Statistics
- Price/Earnings (Normalized)
- 5.72
- Price/Sales
- 4.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,796
- Website
- https://www.hutch-med.com
Valuation
Metric | HCM |
|---|---|
Price/Earnings (Normalized) | 5.72 |
Price/Book Value | 2.09 |
Price/Sales | 4.82 |
Price/Cash Flow | 45.33 |
Price/Earnings
HCM
Financial Strength
Metric | HCM |
|---|---|
Quick Ratio | 5.45 |
Current Ratio | 5.64 |
Interest Coverage | — |
Quick Ratio
HCM
Profitability
Metric | HCM |
|---|---|
Return on Assets (Normalized) | 2.11% |
Return on Equity (Normalized) | 2.98% |
Return on Invested Capital (Normalized) | 2.74% |
Return on Assets
HCM
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|yxn!%#b | LOCK|tw!PM | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|g!?p^tt | LOCK|Z$#$? | $48B | |||
| Haleon PLC ADR HLN | LOCK|<^TK?Xg | LOCK|#D& | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|%%!@y^FG | LOCK|n< | $32B | |||
| Viatris Inc VTRS | LOCK|>#<q!<< | LOCK|$Q% | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|%# | LOCK|mN | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|LdggL& | LOCK|Vc? | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|!!wbF^ | LOCK|%#P | $6B | |||
| Perrigo Co PLC PRGO | LOCK|%TSG^x | LOCK|YX | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|^mp^^$ | LOCK|Pw^! | $2B |
United States